ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > STAT3

STAT3

概要

Name:Signal transducer and activator of transcription 3
Target Synonym:Acute-phase response factor,APRF,STAT3,Signal Transducer And Activator Of Transcription 3 (Acute-Phase Response Factor),Signal transducer and activator of transcription 3,DNA-Binding Protein APRF,ADMIO1,ADMIO,HIES,STAT3 Transcription Factor
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
ST3-H5149 Human Human STAT3 Protein, His Tag (MALS & SPR verified)
ST3-H5149-structure
ST3-H5149-sds
ACRO Quality

生物活性データの一部

ST3-H5149-SPR
STAT3 SPR

Human STAT3, His Tag (Cat. No. ST3-H5149) immobilized on CM5 Chip can bind STAT3 degrader with an affinity constant of 44.6 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Protocol
ST3-H5149-BLI
STAT3 BLI

Loaded Human STAT3, His Tag (Cat. No. ST3-H5149) on NTA Biosensor, can bind STAT3 degrader with an affinity constant of 29.4 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

Synonym Name

STAT3, signal transducer and activator of transcription 3

Background

Signal transducer and activator of transcription 3 (STAT3) regulates the expression of genes important for essential cellular processes including survival, proliferation, self-renewal, angiogenesis, and immune response. As an early tumor diagnostic marker, it is considered that constitutive STAT3 activation is a sufficient factor to cause malignant transformation and tumor development in model systems. The classical IL-6/STAT3 signaling pathway in cancer cells. IL-6 binds to the membrane-bound IL-6 receptor α (IL-6R) and IL-6 receptor β (also known as gp130). The IL-6/IL-6R/gp130 complex activate the phosphorylation of JAKs, followed by STAT3 phosphorylation and activation. Then, phosphorylated STAT3 forms a homodimer and translocates into the nucleus to bind to the promotor region of target genes and activates target gene transcription.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Golotimod SCV-07 Approved Verta Russian Federation Hepatitis C; Mucositis null 2009-01-01 Head and Neck Neoplasms; Hepatitis C; Mucositis; Stomatitis Details
Caffeic Acid CABE Approved The University Of Texas MD Anderson Cancer Center, Moleculin Llc Hemorrhage; Leukopenia; Thrombocytopenia Details
Golotimod SCV-07 Approved Verta Russian Federation Hepatitis C; Mucositis null 2009-01-01 Head and Neck Neoplasms; Hepatitis C; Mucositis; Stomatitis Details
Caffeic Acid CABE Approved The University Of Texas MD Anderson Cancer Center, Moleculin Llc Hemorrhage; Leukopenia; Thrombocytopenia Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Napabucasin DP1; DP2A; BB-608; GB-201; BBI-608; BBI-608-DP1; BBI-608-DP2A; Z1HHM49K7O (UNII code) Phase 3 Clinical 1globe Biomedical Co Ltd, Pharmaceutics International Inc, Boston Biomedical Inc Hematologic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Glioblastoma; Mesothelioma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details
Nanocurcumin (Tehran University of Medical Sciences) Phase 2 Clinical Tehran University Of Medical Sciences Neoplasms; Periapical Diseases Details
OPB-111077 OPB-111077 Phase 2 Clinical Otsuka Pharmaceutical Co Ltd Lymphoma, B-Cell; Solid tumours; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Leukemia, Myeloid, Acute; Carcinoma, Hepatocellular Details
Danvatirsen AZD-9150; STAT-3Rx; ISIS-345794; ISIS-481464; ISIS-STAT3Rx; IONIS-STAT3Rx; ISIS-STAT3-2.5Rx; IONIS-STAT3-2.5Rx Phase 2 Clinical Ionis Pharmaceuticals Inc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Mismatch Repair Deficient Cancer; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Ascites; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms Details
HL-237 HL-237 Phase 2 Clinical Hanlim Pharmaceutical Co Ltd Arthritis, Rheumatoid Details
M-1001 M-1001; MEDICA-M1001 Phase 2 Clinical Syndromex Dyslipidemias Details
NT-219 NT-219; NT219 Phase 2 Clinical TyrNovo Ltd Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Neoplasm Metastasis Details
Dimethylaminomicheliolide Fumarate ACT-001 Phase 2 Clinical Tianjin Accendatech Technology Co Ltd Glioblastoma; Small Cell Lung Carcinoma; Ganglioglioma; Central Nervous System Neoplasms; Optic Neuritis; Neuromyelitis Optica; Breast Neoplasms; Glioma; Brain metastases; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma Details
C-188-9 C188-9; C-188-9; TTI-101 Phase 2 Clinical Baylor College Of Medicine Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Idiopathic Pulmonary Fibrosis; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
WP-1066 WP-1066 Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Medulloblastoma; Glioblastoma; Neoplasms; Brain Neoplasms; Brain metastases; Glioma; Melanoma Details
YY-201 YY-201; YY201 Phase 1 Clinical Shanghai Yuyao Biotechnology Co Ltd Hematologic Neoplasms; Solid tumours; Prostatic Hyperplasia Details
GLG-302 GLG-302; GLG-805; S31-201; NSC-74859 Phase 1 Clinical H Lee Moffitt Cancer Center & Research Institute Breast Neoplasms Details
MOL-4239 MOL-4239; WP-1220 Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Psoriasis; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides Details
Amcasertib/Napabucasin Phase 1 Clinical Boston Biomedical Inc Neoplasms Details
KT-333 KT-333; I-003 Phase 1 Clinical Kymera Therapeutics Inc Lymphoma, T-Cell, Peripheral; Solid tumours; Leukemia, Lymphoid; Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic Details
VVD-130850 VVD-130850; BAY-3630914 Phase 1 Clinical Vividion Therapeutics Inc Solid tumours Details
[14C]ACT-001 [14C]ACT001 Phase 1 Clinical Tianjin Xinyi Shangde Biomedical Technology Co Ltd Solid tumours Details
DCR-STAT3 DCR-STAT3 Phase 1 Clinical Dicerna Pharmaceuticals Inc Solid tumours; Neoplasms Details
OPB-171775 OPB-171775 Phase 1 Clinical Otsuka Pharmaceutical Co Ltd Metabolic Dysfunction-Associated Steatotic Liver Disease Details
Napabucasin DP1; DP2A; BB-608; GB-201; BBI-608; BBI-608-DP1; BBI-608-DP2A; Z1HHM49K7O (UNII code) Phase 3 Clinical 1globe Biomedical Co Ltd, Pharmaceutics International Inc, Boston Biomedical Inc Hematologic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Glioblastoma; Mesothelioma; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details
Nanocurcumin (Tehran University of Medical Sciences) Phase 2 Clinical Tehran University Of Medical Sciences Neoplasms; Periapical Diseases Details
OPB-111077 OPB-111077 Phase 2 Clinical Otsuka Pharmaceutical Co Ltd Lymphoma, B-Cell; Solid tumours; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Carcinoma; Leukemia, Myeloid, Acute; Carcinoma, Hepatocellular Details
Danvatirsen AZD-9150; STAT-3Rx; ISIS-345794; ISIS-481464; ISIS-STAT3Rx; IONIS-STAT3Rx; ISIS-STAT3-2.5Rx; IONIS-STAT3-2.5Rx Phase 2 Clinical Ionis Pharmaceuticals Inc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Mismatch Repair Deficient Cancer; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Ascites; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms Details
HL-237 HL-237 Phase 2 Clinical Hanlim Pharmaceutical Co Ltd Arthritis, Rheumatoid Details
M-1001 M-1001; MEDICA-M1001 Phase 2 Clinical Syndromex Dyslipidemias Details
NT-219 NT-219; NT219 Phase 2 Clinical TyrNovo Ltd Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Neoplasm Metastasis Details
Dimethylaminomicheliolide Fumarate ACT-001 Phase 2 Clinical Tianjin Accendatech Technology Co Ltd Glioblastoma; Small Cell Lung Carcinoma; Ganglioglioma; Central Nervous System Neoplasms; Optic Neuritis; Neuromyelitis Optica; Breast Neoplasms; Glioma; Brain metastases; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma Details
C-188-9 C188-9; C-188-9; TTI-101 Phase 2 Clinical Baylor College Of Medicine Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Idiopathic Pulmonary Fibrosis; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
WP-1066 WP-1066 Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Medulloblastoma; Glioblastoma; Neoplasms; Brain Neoplasms; Brain metastases; Glioma; Melanoma Details
YY-201 YY-201; YY201 Phase 1 Clinical Shanghai Yuyao Biotechnology Co Ltd Hematologic Neoplasms; Solid tumours; Prostatic Hyperplasia Details
GLG-302 GLG-302; GLG-805; S31-201; NSC-74859 Phase 1 Clinical H Lee Moffitt Cancer Center & Research Institute Breast Neoplasms Details
MOL-4239 MOL-4239; WP-1220 Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Psoriasis; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides Details
Amcasertib/Napabucasin Phase 1 Clinical Boston Biomedical Inc Neoplasms Details
KT-333 KT-333; I-003 Phase 1 Clinical Kymera Therapeutics Inc Lymphoma, T-Cell, Peripheral; Solid tumours; Leukemia, Lymphoid; Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic Details
VVD-130850 VVD-130850; BAY-3630914 Phase 1 Clinical Vividion Therapeutics Inc Solid tumours Details
[14C]ACT-001 [14C]ACT001 Phase 1 Clinical Tianjin Xinyi Shangde Biomedical Technology Co Ltd Solid tumours Details
DCR-STAT3 DCR-STAT3 Phase 1 Clinical Dicerna Pharmaceuticals Inc Solid tumours; Neoplasms Details
OPB-171775 OPB-171775 Phase 1 Clinical Otsuka Pharmaceutical Co Ltd Metabolic Dysfunction-Associated Steatotic Liver Disease Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap